No AccessJournal of UrologyAdult Urology1 Nov 2015

Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer

    View All Author Information


    Limited literature exists regarding the safety of testosterone therapy in men treated for prostate cancer. We present multi-institutional data on testosterone therapy in hypogonadal men with prostate cancer treated with radiation therapy.

    Materials and Methods:

    We retrospectively reviewed the records of hypogonadal men treated with testosterone therapy after radiation therapy for prostate cancer at 4 institutions. Serum testosterone, free testosterone, estradiol, sex hormone-binding globulin, prostate specific antigen, prostate specific antigen velocity and prostate biopsy findings were analyzed.


    A total of 98 men were treated with radiation therapy. Median age was 70.0 years (range 63.0 to 74.3) at initiation of testosterone therapy. Median baseline testosterone was 209 ng/dl (range 152 to 263) and median baseline prostate specific antigen was 0.08 ng/ml (range 0.00 to 0.33). In the cohort the tumor Gleason score was 5 in 3 men (3.1%), 6 in 44 (44.9%), 7 in 28 (28.6%), 8 in 7 (7.1%) and 9 in 4 (4.1%). Median followup was 40.8 months (range 1.5 to 147). Serum testosterone increased to a median of 420 ng/dl (range 231 to 711) during followup (p <0.001). Overall a nonsignificant increase in mean prostate specific antigen was observed from 0.08 ng/ml at baseline to 0.09 ng/ml (p = 0.05). Among patients at high risk prostate specific antigen increased from 0.10 to 0.36 ng/ml (p = 0.018). Six men (6.1%) met criteria for biochemical recurrence.


    Testosterone therapy in men following radiation therapy for prostate cancer was associated with a minor increase in serum prostate specific antigen and a low rate of biochemical recurrence.


    • 1 : Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007; 92: 4241. Google Scholar
    • 2 : Graham P and Members of British Columbia Cancer Agency Prostate Cohort Outcomes Initiative: What happens to testosterone after prostate radiation monotherapy and does it matter?. J Urol2002; 167: 2448. LinkGoogle Scholar
    • 3 : Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol2006; 50: 935. Google Scholar
    • 4 : Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol2004; 172: 920. LinkGoogle Scholar
    • 5 : Testosterone replacement therapy after primary treatment for prostate cancer. J Urol2005; 173: 533. LinkGoogle Scholar
    • 6 : Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol2013; 190: 639. LinkGoogle Scholar
    • 7 : Testosterone replacement therapy following radical prostatectomy. J Sex Med2009; 6: 1165. Google Scholar
    • 8 : Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res2013; 25: 24. Google Scholar
    • 9 : Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int2014; 114: 125. Google Scholar
    • 10 : Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int2009; 103: 62. Google Scholar
    • 11 : Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer2007; 109: 536. Google Scholar
    • 12 : Testosterone therapy in men with untreated prostate cancer. J Urol2011; 185: 1256. LinkGoogle Scholar
    • 13 : Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol2005; 173: 797. LinkGoogle Scholar
    • 14 : Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA2006; 296: 2351. Google Scholar
    • 15 : Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol2003; 170: 2348. LinkGoogle Scholar
    • 16 : Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol2010; 58: 838. Google Scholar
    • 17 : Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys2003; 57: 19. Google Scholar
    • 18 : Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA1999; 281: 1598. Google Scholar
    • 19 : Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys1998; 41: 491. Google Scholar
    • 20 : Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys1997; 38: 311. Google Scholar
    • 21 : Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol2002; 168: 9. LinkGoogle Scholar
    • 22 : Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst2008; 100: 170. Google Scholar
    • 23 : Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol2012; 62: 757. Google Scholar
    • 24 : The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis2014; 17: 132. Google Scholar
    • 25 : Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol2009; 55: 310. Google Scholar
    • 26 : Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol2011; 186: 1005. LinkGoogle Scholar
    • 27 : Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med2014; 11: 2818. Google Scholar
    • 28 : Serum PSA as a predictor of testosterone deficiency. J Sex Med2013; 10: 2518. Google Scholar
    • 29 : Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl2014; 16: 864. Google Scholar